0001079973-23-000412 Sample Contracts

Logo] BENCHMARK

Cardio Diagnostics Holdings, Inc. • March 31st, 2023 • In vitro & in vivo diagnostic substances • New York

• Company
  Cardio Diagnostics Holdings, Inc.
• Filed
  March 31st, 2023
• Industry
  In vitro & in vivo diagnostic substances
• Jurisdiction
  New York

AMENDMENT NO. 1 ENGAGEMENT LETTER

Cardio Diagnostics Holdings, Inc. • March 31st, 2023 • In vitro & in vivo diagnostic substances

• Company
  Cardio Diagnostics Holdings, Inc.
• Filed
  March 31st, 2023
• Industry
  In vitro & in vivo diagnostic substances

Amendment 1 dated November 14, 2022 (this “Amendment”) to the Engagement Letter dated as of May 13, 2022 between The Benchmark Company, LLC (“Benchmark”) and Cardio Diagnostics, Inc. [sic] (“Company”).